Published in final edited form as:

Alzheimers Dement. 2015 August ; 11(8): 994–1004. doi:10.1016/j.jalz.2015.01.006.

Florbetapir PET, FDG PET, and MRI in Down Syndrome Individuals with and without Alzheimer's Dementia

Marwan N. Sabbagh, MD^{1,2,7}, Kewei Chen, PhD^{2,3,4}, Joseph Rogers, PhD⁵, Adam S. Fleisher, MD^{2,3}, Carolyn Liebsack, BSN^{1,2}, Dan Bandy, MS^{2,3}, Christine Belden, PsyD^{1,2}, Hillary Protas, Ph.D^{2,3}, Pradeep Thiyyagura, MS^{2,3}, Xiaofen Liu, MS^{2,3}, Auttawut Roontiva, MS^{2,3}, Ji Luo, MS^{2,3}, Sandra Jacobson, MD^{1,2}, Michael Malek-Ahmadi, MSPH^{1,2}, Jessica Powell, PsyD^{1,2}, and Eric M. Reiman, MD^{2,3,6,7}

¹Banner Sun Health Research Institute

²Arizona Alzheimer's Consortium

³Banner Alzheimer's Institute

⁴Arizona State University

⁵SRI International

⁶Translational Genomics Research Institute

Corresponding Author: Marwan N. Sabbagh, MD, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, Phone (623) 832-6500, FAX (623) 832-6504, marwan.sabbagh@bannerhealth.com.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author Contributions Marwan Sabbagh, MD (marwan.sabbagh@bannerhealth.com)—Conception and design of study, acquisition and interpretation of data, drafting of article, and final approval of the version to be published.

Kewei Chen, PhD (kewei.chen@bannerhealth.com)—Analysis and interpretation of data, revision of article, final approval of the version to be published.

Joseph Rogers, PhD (joseph.rogers@sri.com)—Subject recruitment, interpretation of data, revision of article, final approval of the version to be published.

Adam S. Fleisher, MD (adam.fleisher@bannerhealth.com)—Design of study, acquisition and interpretation of data, revision of article, and final approval of the version to be published.

Carolyn Liebsack, RN (Carolyn.liebsack@bannerhealth.com), Coordinated the study.

Dan Bandy, MS (dan.bandy@bannerhealth.com), Oversaw all imaging MRI and PET done to ensure technical quality

Christine Belden, PsyD (Christine.Belden@bannerhealth.com) administered cognitive measures and selected the cognitive instruments

Pradeep Thiyyagura MS (Pradeep.thiyyagura@bannerhealth.com) provided image analysis

Xiaofen Liu, MS (xiaofen.liu@bannerhealth.com) provided image analysis

Auttawut Roontiva, MS (Auttawut.roontiva@bannerhealth.com), provided image analysis

Ji Luo, MS (ji.luo@bannerhealth.com), provided image analysis

Hillary Protas, Ph.D (hillary.protas@bannerhealth.com), provided image analysis

Sandra Jacobson, MD, (Sandra.jacobson@bannerhealth.com) evaluated subjects

Michael Malek-Ahmadi, MSPH , (michael.ahmadi@bannerhealth.com) performed cognitive assessment and statistical analysis

Jessica Powell PsyD, (Jessica.powell@bannerhealth.com) performed cognitive assessments

Eric M. Reiman, M.D. (eric.reiman@bannerhealth.com)—Design of study, interpretation of data, revision of article, a final approval of the version to be published.

Responsibility for Manuscript:

Marwan Sabbagh, MD, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflicts of Interest: All authors declare that they have no material conflicts of interest with respect to the present study, as defined by the ICMJE guidelines.

⁷University of Arizona

Abstract

Since Down syndrome (DS) is associated with amyloid β (A β) deposition, we characterized imaging measurements of regional fibrillar A β burden, cerebral metabolic rate (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD+), 12 DS without dementia (DS/AD-), and 9 normal controls (NCs). There were significant group differences in mean SUVRs for florbetapir with DS/AD+ having the highest, followed by DS/AD-, followed by NC. For FDG-PET, posterior cingulate rCMRgl in DS/AD+ was significantly reduced compared to DS/AD- and NC. For vMRI, hippocampal volumes were significantly reduced for the DS/AD+ compared to DS/AD- and NC. Age-related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs. DS is associated with fibrillar A β , rCMRgl, and l rGMV alterations in the dementia stage and prior to the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.

INTRODUCTION

Down Syndrome (DS) is characterized by partial to complete trisomy of chromosome 21, developmental delay, and other developmental abnormalities. DS is also associated with a significant increase in the risk of Alzheimer's disease (AD).¹ This increased AD risk is generally believed to be due to trisomy of the amyloid precursor protein (APP) gene, which resides on the distal arm of chromosome 21. Presumably, possession of an extra copy of the APP gene induces APP over-expression, accounting for the virtually universal presence of fibrillar amyloid β peptide (A β) neuropathology in autopsied DS patients over the age of 35.^{2,3}

AD dementia occurs in approximately 10-25% of persons with DS in their 40s, 20-50% of those in their 50s, and 60-75% of those over the age of 60.²⁻⁴ Due especially to improvements in the treatment of DS-related cardiac anomalies, more persons with DS are living to older ages.⁵ Given their increased risk for AD, there is a critical and largely unmet need to characterize the clinical and biomarker changes associated with preclinical and clinical stages of AD in DS individuals.

To date, the best established brain imaging methods for preclinical and clinical evaluation of AD include positron emission tomography (PET) measurements of fibrillar A β burden, reductions in regional PET measurements of the cerebral metabolic rate for glucose (CMRgl), and magnetic resonance imaging (MRI) measurements of regional and whole brain volumes. These imaging techniques have been used successfully in a small number of studies to detect and track characteristic brain alterations in DS.⁶⁻¹⁷ To our knowledge, though, no reported studies have yet characterized all three measurements in the assessment of DS patients, and only one has reported findings in DS individuals with and without AD dementia.⁶

The primary objective in this small cross-sectional study was to use PET measurements of fibrillar A β burden, PET measurements of regional CMRgl, and MRI measurements of

hippocampal and regional gray matter volumes to identify age-related brain imaging alterations associated with preclinical and clinical AD dementia in individuals with DS. Clinical, functional, and neuropsychological findings provided secondary outcomes of interest. These findings could establish a cohort for longitudinal research of AD biomarker assessments in DS and help set the stage for the evaluation of interventions to treat and prevent AD dementia in this at-risk population.

METHODS

Subjects

Five DS participants with the clinical diagnosis of Alzheimer's dementia (DS/AD+), 12 DS participants without the clinical diagnosis of Alzheimer's dementia (DS/AD-), and 9 normal controls (NCs) were enrolled in the study (Table 1). Participants and/or their caregivers/legal guardians provided informed consent, and the participants were studied under protocols approved by our organization's Institutional Review Board. DS/AD+ participants met DSM-IV and NIA-Alzheimer's Association diagnostic criteria for AD dementia by informant report of progressive cognitive decline with clear historical evidence of functional decline from premorbid abilities.¹⁸ DS/AD- participants had neither evidence of progressive cognitive nor functional decline.

While the standard diagnostic criteria from the DSM-IV are not modified specifically for individuals with intellectual disability, it is stated within these criteria that change from a previous level of function is required for a diagnosis. Specifically, "The cognitive deficits in Criteria A1 and A2 (memory, language, executive functioning etc) each cause significant impairment in social or occupational functioning and represent a significant decline from a previous level of functioning". The study lead here is a neurologist with a large number of patients in his practice and is familiar with premorbid deficits in Down syndrome (on average). We were careful to query parents/caregivers about noted changes in their daily life, much like is emphasized in a number of dementia screeners for ID currently in development (NTG screener from the National Task Group on Intellectual Disabilities and Dementia Practices- not available at the start of this study)."

The DS/AD+ and DS/AD- subjects had no history of epilepsy or seizures and their neurological exams were non-focal. NC participants were cognitively normal, without trisomy 21, and matched for age to the DS/AD- group. All DS subjects were confirmed by chromosome testing to have trisomy 21. Exclusion criteria included a lifetime history of another neurodegenerative disease, vascular dementia, or psychiatric disorders. Except as noted below, a medical history, physical exam, clinical evaluation, functional and neuropsychological testing, chromosome testing, and brain imaging were performed in all subjects. One DS/AD- participant withdrew consent after florbetapir PET scan and was not subsequently assessed by MRI. An additional DS/AD+ subject, who was severely impaired and agitated during imaging procedures, was excluded from the study due to extremely poor PET and MRI imaging quality. All other participants were evaluated with both florbetapir PET and MRI.

Clinical, Functional and Neuropsychological Tests

All participants completed the Dementia Questionnaire for People with Learning Disabilities (DLD),¹⁹ the mini-mental state exam (MMSE),²⁰ the Brief Praxis Test,²¹ the severe impairment battery (SIB),²² and the Vineland Adaptive Behavior Scale, Second edition (see Table 1).²³ Premorbid IQ estimation was not available from records, nor was it assessed as part of the study.

[18F] Florbetapir PET acquisition and pre-processing

Florbetapir PET imaging was used to assess mean cortical-to-pontine florbetapir standard uptake value ratios (SUVRs) as the primary outcome measure of fibrillar A β burden. As in our previous florbetapir study,⁷ participants underwent a 10 minute emission scan 50 minutes after intravenous injection of 10 mCi (370 MBq) of [18F] florbetapir. Scans were performed on a Siemens Biograph XVI HiRez PET/CT scanner. The images were reconstructed using an iterative reconstruction algorithm (4 iterations, 16 subsets), with a 5 mm full-width at half-maximum Gaussian filter, and were corrected for radiation attenuation and scatter. If significant patient motion was observed, another 10-minute scan was acquired. SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/>) was used to linearly and nonlinearly deform each subject's florbetapir PET image into Montreal Neurological Institute (MNI) standard coordinate space with cubic voxel size of 2x2x2 mm and to smooth with 5mm full-width-at-half-maximum Gaussian kernel.

Mean cortical-to-pontine SUVRs were computed using measurements from a pontine region of interest (ROI) using six automatically defined bilateral (frontal, temporal, parietal, anterior cingulate, posterior cingulate [PC], and precuneus) ROIs. Due to increased cerebellar uptake in the clinical stages of autosomal dominant AD²⁴, another form of AD that, like DS, is associated with genetically-driven increases in A β production, pons was employed as the reference region. SUVRs were typically less than 1.0 due to the relatively high non-specific binding in pons. In post-hoc analyses, SUVRs were characterized in each of the six cortical, thalamic, and striatum ROIs, and patterns of SUVR increases were characterized using the automated brain mapping routine in SPM8.

[18F]-Fluorodeoxyglucose (FDG) PET acquisition and pre-processing

FDG PET was used to compare regional cerebral glucose metabolism across groups. Because reduced PC CMRgl is a relatively early indicator of AD in patients affected by and at risk for late-onset and autosomal dominant AD dementia,²⁵ data from an automatically defined PC ROI were used as the primary rCMRgl outcome measure. Please note the CMRgl (or rCMRgl) we referred to in this study was a unit-less semi-quantitative ratio of the PET counts from target region such as PC ROI over the counts from the whole brain. In this our rCMRgl is SUVR with whole brain as the reference region. Six 5-minute emission frames were acquired on the same PET/CT system 30 minutes after the intravenous administration of 5 mCi of [18F] FDG. FDG PET images were reconstructed, filtered, and corrected for radiation attenuation and scatter using the same procedures employed for reconstruction of florbetapir PET images. The six emission frames were aligned and averaged. As with the florbetapir data, SPM8 was used to linearly and nonlinearly deform each subject's averaged FDG PET image into MNI standard coordinate space, to normalize

individual images for the variation in whole brain PET counts using proportionate scaling (*i.e.*, our unit-less CMRgl or SUVR) and to smooth with 5mm full-width-at-half-maximum Gaussian kernel. In post hoc analyses, rCMRgl patterns were compared using the automated brain mapping routine in SPM8²⁶.

MRI data acquisition and pre-processing

FreeSurfer estimated hippocampal volume (relative to intracranial volume, a unit-less measure) was the primary MRI outcome measure. MRI was performed using a 1.5-T Signa system (General Electric) and a T1-weighted volumetric pulse sequence (IRSPGR; repetition time = 33 ms; echo time = 5 ms; $\alpha = 30^\circ$; number of excitations = 1; field of view = 24 cm; 256 X 192 imaging matrix; slice thickness = 1.5 mm; 124 slices; scan time = 13:36 minutes). A T2 weighted FLAIR image was used to exclude the presence of strokes and edema and a long TE gradient echo acquisition was used for the assessment of microhemorrhages.

Hippocampal-to- intracranial volume ratios were characterized from bilateral ROIs in each participant's T1-weighted MRI using the FreeSurfer 5.1 software package (<http://surfer.nmr.mgh.harvard.edu>)²⁷⁻²⁹. All images were visually inspected to verify ROI characterization.

Voxel-wise measurements of regional gray matter volume (rGMV, corrected for total intracranial volume) were determined using the voxel-based morphometry (VBM) routine and DARTEL (Diffeomorphic Anatomical Registration using Exponential Lie Algebra) protocol in SPM8.³⁰⁻³² The gray matter partitions generated by this process in the MNI template space preserve the total amount of tissue from the native space images. This preservation is via voxelby-voxel multiplication of the determinant of the Jacobian matrix for the non-linear deformation only. The gray matter map for each subject was smoothed with an 8mm full-width-at-half- maximum Gaussian kernel. In post-hoc analyses, rGMV patterns were compared using the automated brain mapping routine in SPM8.

Statistical analysis

To compare DS/AD+, DS/AD-, and NC groups, we assessed primary (florbetapir PET, FDG PET, and volumetric MRI) and secondary (clinical exam and functional and neuropsychological testing) outcomes using one-way ANOVAs. Where dictated by *a priori* hypotheses, significant outcomes were additionally assessed by between-group t-tests. Each primary outcome measure also was evaluated for its association with age. Here, DS groups were pooled to provide a more complete span of ages, and a general linear model was employed to determine whether or not the slope for a particular variable (plotted against age) deviated significantly from zero. Age-related differences between the DS group as a whole and the NC group were evaluated by comparing the age-associated slopes age by group interaction for each variable between groups, the same way as applied in a previous study.³³ Alpha = 0.05 was used for all primary measures. For the post-hoc brain mapping analyses, $P = 0.001$, uncorrected for multiple comparisons, was employed to provide information about the pattern of between-group differences in each brain imaging measurement. Summary data are given throughout as mean $\pm$ standard deviation.

RESULTS

Participants' demographic characteristics and clinical, functional, and neuropsychological test scores are shown in Table 1. The AD/DS+ group was significantly older than the DS/AD- and NC groups. As predicted, the DS groups performed significantly less well than the NC group, and the DS/AD+ group performed significantly less well than the DS/AD- group, on most of the clinical and neuropsychological tests.

Figure 1a shows comparisons on the three primary outcome measures. There were significant group differences in mean cortical-to-pontine SUVRs, with DS/AD+ (1.14 ± 0.13) followed by DS/AD- (0.94 ± 0.07) followed by NC (0.80 ± 0.03) (linear trend ANOVA $P < 1.0e-6$). PC-to-whole brain CMRgl also differed significantly between the groups, with DS/AD+ (1.32 ± 0.20), DS/AD- (1.54 ± 0.18), and NC (1.76 ± 0.16) demonstrating the lowest-to-highest readings, respectively (linear trend ANOVA $P < 0.001$). Hippocampal GMVs, however, did not exhibit significant group differences, with similar mean values for DS/AD+ (0.005 ± 0.0007), DS/AD- (0.0052 ± 0.0006), and NC (0.0049 ± 0.00033) (linear trend ANOVA $P = 0.12$). Associations between age and the increase in mean cortical SUVR and decline in PC CMRgl were significantly greater in the overall DS group than in the NC group ($P = 0.015$ and $P = 0.011$, respectively), whereas the associations between age and hippocampal GMV decline were not ($P = 0.85$) (Figure 1b). In post-hoc ROI analyses, there were significant between-group florbetapir SUVR differences in the frontal ($P = 1e-5$), temporal ($P = 1e-6$), parietal ($P = 8e-6$), anterior cingulate, ($P = 1e-6$), PC ($P = 5e-6$), precuneus ($P = 2e-6$), and striatum ($P = 6e-6$) ROIs, and a non-significant trend in the thalamic ROI ($P = 0.054$).

The statistical brain maps in Figures 2-4 show locations with significantly greater SUVRs, lower regional CMRgl, and lower regional GMV in a) the DS/AD+ compared to NC group, b) the DS/AD+ compared to DS/AD- group, and c) the DS/AD- compared to NC group, respectively ($P = 0.001$ in all comparisons).

The DS groups had significantly higher florbetapir SUVRs than the NC group bilaterally in the vicinity of posterior and anterior cingulate, precuneus, parietal, temporal, frontal, and striatal regions (Figures 2a, row A and C), similar to patterns in the clinical and preclinical stages of late-onset AD in published reports.^{24,34} These results were still apparent after controlling for age. The magnitude of increase was significantly greater in DS/AD+ (Figure 2a Row B).

The DS/AD+ group was distinguished from the DS/AD- and NC groups by significantly lower CMRgl bilaterally in the vicinity of PC, lateral parietal, and temporal and frontal regions, which have been previously shown to be preferentially affected in the clinical and preclinical stages of late-onset AD (Figures 3a row A and C)^{35,36}. The DS/AD+ and DS/AD- groups were also distinguished from the NC group by significantly lower CMRgl in the vicinity of additional medial frontal regions.

The DS/AD+ group had significant regional gray matter reduction compared to NC (Figure 4a Row A) and to DS/AD- groups (Figure 4a Row B). The most prominent reductions were in bilateral basal, medial, and pre-frontal lobes, bilateral temporal lobes, lateral parietal

cortex, and precuneus. However, lateral parietal cortex and precuneus changes in the DS/AD+ versus NC comparison became non-significant after accounting for age effects. DS/AD- subjects also had lower volumetric MRI measures than NC subjects in the medial, prefrontal, and occipital lobes (Figure 4a Row C).

The DS/AD+ group was distinguished from the DS/AD- and NC groups by significantly lower GMV bilaterally in the vicinity of PC, parietal, temporal, and frontal regions, which are preferentially affected by AD³⁷. The DS/AD+ and DS/AD- groups were also distinguished from the NC group by significantly lower GMV in the vicinity of additional medial frontal regions, which we again postulate to reflect differences in brain development. In addition to the voxel-wise correlation with cog scores, we also examined such correlations for the primary image outcomes (AV45: mean-cortical SUVR, FDG: posterior cingulate, MRI: hippocampus volume): The correlation is significant for florbetapir SUVR, for FDG-PET CMRgl, but not for hippocampus volume.

Cognitive measures did not differ significantly between DSAD+ and DSAD-. Table 2 summarizes the correlations between cognitive measures and imaging parameters. The SIB appears to correlate better with imaging modalities than other cognitive measures.

DISCUSSION

This brain imaging study provides new information about the fibrillar A β , CMRgl, and GMV alterations associated with the clinical and preclinical stages of AD in participants with DS. DS subjects had florbetapir PET evidence of fibrillar A β burden in the symptomatic dementia stage. Further, fibrillar A β was detected in DS subjects without evidence of cognitive decline (DS/AD-) as early as 35 years of age (see figure 1). Increases in florbetapir uptake were associated with dementia status and older age. More specifically, florbetapir uptake strongly increases with and correlates with age. DS participants with AD dementia also had lower CMRgl and GMV in brain regions known to be preferentially affected by late-onset AD. Finally, DS participants with and without dementia had lower CMRgl and GMV than NC subjects in additional frontal regions. We believe these latter alterations may reflect differences in brain development.

In this study, we used pons as the reference region for the examination of amyloid deposits measured by florbetapir. Such practice was based on its previous use in the autosomal dominant AD subjects²⁴. We felt that given the similarity between PS1 and DS as amyloid overproducing conditions, this methodology was appropriate to use. In addition, neuropathological studies have suggested the presence of cerebellar amyloid deposition in the clinical stages of early-onset amyloid- β (A β) overproducing syndromes, including autosomal dominant AD mutation carriers and patients with Down syndrome). Interestingly, our results showed the greater cerebellar SUVR in DS/AD+ than in DS/AD- or in NC group, and in DS/AD- than in NC. Rather than that, the overall amyloid pattern findings are similar using either Pons or cerebellum as the reference region.

Cognitive measures did not differ significantly between DSAD+ and DSAD-. This is likely due to smaller sample size and the possibility that the tests were not as sensitive as the

neuroimaging based biomarkers. Our study was not designed to examine the difference between DSAD+/- subjects. Rather one of our focuses was to examine the earliest changes we can detect in DS subjects compared to the NC (the age trajectory of various biomarkers).

A small number of published studies have used PET to characterize fibrillar A β burden in persons with DS.⁶⁻⁹ For instance, Handen et al used Pittsburgh Compound B (PiB) PET to study seven 20-44 year-old DS/AD- participants and found evidence of fibrillar A β burden in the two individuals who were at least 38 years of age.⁹ Landt et al used PiB PET to study five DS/AD+ participants, four DS/AD- participants, and 14 NCs and found evidence of fibrillar A β burden after the age of 45.⁶ Both PiB PET studies found preferential evidence of fibrillar A β deposition in the striatum, similar to that found in some PiB studies of autosomal dominant AD mutation carriers. Nelson et al used fluoroethyl-methylamino]-naphthyl-ethylidene malononitrile PET to investigate fibrillar and tau burden in 19 (mean age 36,7 years-old) DS/AD- participants and reported increased SUVRs in brain regions similar to that observed in late onset AD.⁸ We previously used florbetapir PET to characterize fibrillar A β burden in an end-of-life DS/AD+ participant⁷. Here, we found a regional pattern of fibrillar A β deposition similar to that observed in late-onset AD⁷. In our florbetapir PET study of PSEN1 E280A mutation carriers, we also found a regional pattern of fibrillar A β deposition similar to that observed in late-onset AD^{24,38}. We subsequently confirmed the magnitude and pattern of fibrillar A β deposition at autopsy⁷. We interpret our florbetapir PET data to preferentially affect the same brain regions that might be affected in late-onset AD. While there was a close correlation between antemortem PET and postmortem histopathological measurements of A β plaques in this DS participant with AD dementia, florbetapir PET measurements may be less sensitive to the detection of the primarily diffuse A β plaques that have been reported in virtually all DS/AD- individuals who expired by the age of 35³⁹. Previously published FDG PET studies have reported a pattern of CMRgl reductions in DS adults with and without AD dementia similar to that observed in late-onset AD⁴⁰, consistent with the findings reported in our study. In addition, Haier et al, reported increased inferior and medial temporal CMRgl^{11,12} in middle-aged DS/AD- participants, raising the possibility of compensatory increases in local neuronal activity in preclinical stages of AD.

While we are not aware of previously published volumetric MRI studies in DS/AD+ individuals, previously published volumetric MRI studies have reported alterations in GMV and white matter volume alterations in DS/AD- individuals and their associations with older age.¹⁴⁻¹⁷ For example, Teipel et al.¹⁵ found significant age-related CMV reductions in precuneus, lateral parietal, and temporal, frontal, occipital, and parahippocampal regions in these individuals. Our findings are generally consistent with the GMV findings in those reports and extend them to DS individuals with AD dementia.

In addition to progressive CMRgl and GMV reductions in brain regions known to be preferentially affected by AD, the DS/AD+ and DS/AD- groups had lower CMRgl and GMV than NCs in additional medial and basal frontal regions. Others have identified greater occipital atrophy and relative sparing of both medial and lateral temporal regions on MRI and FDG. While we cannot exclude the possibility that these changes are related to preclinical AD processes that do not continue to progress with age or to clinical severity

after middle age, we postulate that these changes might reflect DS-related alterations in brain development.

Additional studies are needed to a) further characterize and confirm our fibrillar A β , CMRgl, and brain tissue volume findings in a larger number of participants; b) control for the effects of APOE genotypes and premorbid IQs; and c) clarify the extent to which the brain imaging alterations predict subsequent clinical decline. Additional studies also are needed to track these changes over time and provide sample size estimates for the evaluation of preclinical and clinical AD treatments using these brain imaging endpoints in proof-of-concept trials. Additional studies in DS individuals also are needed to characterize the most sensitive indicators of cognitive and functional decline in the preclinical and clinical stages of AD and provide sample size estimates for the evaluation of treatments using these endpoints in license-enabling trials.

DS represents the largest population of individuals at risk for early-onset A β pathology, far exceeding the number of patients who carry autosomal dominant AD mutations. With the growing number of DS individuals living to older ages, there is an urgent need to find effective clinical and preclinical AD treatments in this vulnerable population.⁴¹⁻⁴⁴

Conclusions

DS is associated with characteristic fibrillar A β , regional CMRgl, and regional GMV alterations in the symptomatic dementia stage and prior to onset of cognitive decline. Amyloid signal strongly increases with age in DS. This brain imaging study provides a foundation for the longitudinal studies needed to inform AD treatment and prevention trials in this vulnerable population.

Acknowledgements

Supported by the Banner Sun Health Research Institute, the Arizona Alzheimer's Research Consortium ADHS12-010553, NIA 5P30AG019610-12, Avid Radiopharmaceuticals, and the Banner Alzheimer's Institute. Partly supported by grants from the National Institute on Aging (R01AG031581), the National Institute of Mental Health (R01MH057899), the state of Arizona, and contributions from the Banner Alzheimer's Foundation. The imaging was supported by the AARC ADHS 12-10553 grant. Avid radiopharmaceuticals provided the florbetapir. The other grants supported the time and effort of the investigators on this project.

We are also grateful for the assistance of One Step Beyond, a program for adults with DS, which promoted awareness of our study in the DS community, and the Molly Lawson Foundation, which provided funding for transportation of participants. We also thank Vivek Devadas and Robert Bauer III for their technical supports

References

1. Davidson MA. Primary care for children and adolescents with down syndrome. *Pediatr Clin North Am.* 2008; 55:1099–1111. [PubMed: 18929054]
2. Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of participants under 50 years of age with down's syndrome. *J Neurol Sci.* 1989; 89:169–179. [PubMed: 2522541]
3. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in down's syndrome: Clinicopathologic studies. *Neurology.* 1985; 35:957–61. [PubMed: 3159974]
4. Zigman WB, Lott IT. Alzheimer's disease in Down syndrome: neurobiology and risk. *Ment Retard Dev Disabil Res Rev.* 2007; 13(3):237–46. [PubMed: 17910085]
5. Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. *Eur J Public Health.* Apr; 2007 17(2):221–5. [PubMed: 16857692]

6. Landt J, D'Abrera JC, Holland AJ, et al. Using positron emission tomography and carbon 11-labeled Pittsburgh compound b to image brain fibrillar beta-amyloid in adults with down syndrome: Safety, acceptability, and feasibility. *Arch Neurol*. 2011; 68:890–6. [PubMed: 21403005]
7. Sabbagh MN, Fleisher A, Chen K, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with down syndrome and alzheimer's disease. *Arch Neurol*. 2011; 68:1461–6. [PubMed: 22084131]
8. Nelson LD, Siddarth P, Kepe V, et al. Positron emission tomography of brain β -amyloid and τ levels in adults with Down syndrome. *Arch Neurol*. Jun; 2011 68(6):768–74. [PubMed: 21670401]
9. Handen BL, Cohen AD, Channamalappa U, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. *Alzheimers Dement*. Nov; 2012 8(6): 496–501. [PubMed: 23102120]
10. Pietrini P, Dani A, Furey ML, et al. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. *Am J Psychiatry*. Aug; 1997 154(8):1063–9. [PubMed: 9247390]
11. Haier RJ, Head K, Head E, Lott IT. Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. *Neuroimage*. Feb 1; 2008 39(3):1324–32. [PubMed: 18006337]
12. Head E, Lott IT, Patterson D, Doran E, Haier RJ. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. *J Alzheimers Dis*. Mar; 2007 11(1):61–76. [PubMed: 17361036]
13. Dani A, Pietrini P, Furey ML, et al. Brain cognition and metabolism in Down syndrome adults in association with development of dementia. *Neuroreport*. Nov 25; 1996 7(18):2933–6. [PubMed: 9116213]
14. Teipel SJ, Schapiro MB, Alexander GE, et al. Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. *Am J Psychiatry*. Oct; 2003 160(10):1870–8. [PubMed: 14514503]
15. Teipel SJ, Alexander GE, Schapiro MB, Möller HJ, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. *Brain*. Apr; 2004 127(Pt 4):811–24. [PubMed: 14985261]
16. Krasuski JS, Alexander GE, Horwitz B, Rapoport SI, Schapiro MB. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. *Am J Psychiatry*. Jan; 2002 159(1): 74–81. [PubMed: 11772693]
17. White NS, Alkire MT, Haier RJ. A voxel-based morphometric study of nondemented adults with Down Syndrome. *Neuroimage*. Sep; 2003 20(1):393–403. [PubMed: 14527599]
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May; 2011 7(3):263–9. [PubMed: 21514250]
19. Evenhuis, HM.; Kengen, MMF.; Eurlings, HAL. Screening Instrument for Diagnosis of Dementia in People with Learning Disabilities (2007). UK adaptation, Pearson Assessment; London: 2007.
20. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. *Journal of Psychiatric Research*. 1975; 12:189–198. [PubMed: 1202204]
21. Dalton, A.; Fedor, B. Dyspraxia scale for adults with Down Syndrome. NYS Institute for Basic Research in Developmental Disabilities; 1997.
22. McGonigle KL, Swihart AA, Boller F, Saxton J, McGonigle KL, Swihart AA, Boller F. The Severe Impairment Battery. Harcourt Assessment 1993 London. 1993
23. Sparrow, SS.; Cicchetti, DV.; Balla, DA. Vineland-II: Vineland Adaptive Behavior Scales. 2nd ed.. Pearson; Oxford: 2007.
24. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid- β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. *Lancet Neurol*. Dec; 2012 11(12):1057–65. [PubMed: 23137949]

25. Caselli RJ, Reiman EM. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. *J Alzheimers Dis.* 2013; 33(Suppl 1):S405–16. [PubMed: 22695623]
26. Protas HD, Chen K, Langbaum JB, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. *JAMA Neurol.* Mar 1; 2013 70(3):320–5. [PubMed: 23599929]
27. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron.* 2002; 33:341–355. [PubMed: 11832223]
28. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging.* 2008; 27:685–691. [PubMed: 18302232]
29. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. *IEEE Trans Med Imaging.* 1998; 17:87–97. [PubMed: 9617910]
30. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. *Neuroimage.* Jun; 2000 11(6 Pt 1):805–21. [PubMed: 10860804]
31. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage.* Oct 15; 2007 38(1): 95–113. Epub 2007 Jul 18. [PubMed: 17761438]
32. Ashburner J. Computational anatomy with the SPM software. *Magn Reson Imaging.* Oct; 2009 27(8):1163–74. [PubMed: 19249168]
33. Lane RD, McRae K, Reiman EM, Chen K, Ahern GL, Thayer JF. A Neural correlates of heart rate variability during emotion. *Neuroimage.* 2009; 44:214–223.
34. Rodrigue KM, Kennedy KM, Devous MD, et al. β -Amyloid burden in healthy aging: regional distribution and cognitive consequences. *Neurology.* Feb 7; 2012 78(6):387–95. [PubMed: 22302550]
35. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. *Am.J.Psychiatry.* 2002; 159:738–745. [PubMed: 11986126]
36. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. *Proc Natl Acad Sci U S A.* Jan 6; 2004 101(1):284–9. Epub 2003 Dec 19. [PubMed: 14688411]
37. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. *J.Neurosci.* 2009; 29:15223–15231. [PubMed: 19955375]
38. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. *J Neurosci.* 2007; 27:6174–84. [PubMed: 17553989]
39. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. *Neurobiol Dis.* Feb; 1996 3(1):16–32. [PubMed: 9173910]
40. Azari NP, Pettigrew KD, Pietrini P, Horwitz B, Schapiro MB. Detection of an Alzheimer disease pattern of cerebral metabolism in Down syndrome. *Dementia.* Mar-Apr; 1994 5(2):69–78. [PubMed: 8038869]
41. Kishnani PS, Sommer BR, Handen BL, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. *Am J Med Genet A.* Aug; 2009 149A(8): 1641–54. [PubMed: 19606472]
42. Kishnani PS, Heller JH, Spiridigliozzi GA, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. *Am J Med Genet A.* Dec; 2010 152A(12):3028–35. [PubMed: 21108390]
43. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. *Am J Med Genet A.* Aug; 2011 155A(8):1939–48. [PubMed: 21739598]
44. Kondoh T, Kanno A, Itoh H, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome participants with severe cognitive impairment: a 24-week randomized,

double-blind, placebo-controlled trial. *Int J Psychiatry Med.* 2011; 41(1):71–89. [PubMed: 21495523]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Research in Context

Systematic review:

AD dementia occurs in approximately 10-25% of persons with DS in their 40s, 20-50% of those in their 50s, and 60-75% of those over the age of 60. Given their increased risk for AD, there is a critical and largely unmet need to characterize the clinical and biomarker changes associated with preclinical and clinical stages of AD in DS individuals. A small number of published studies have used PET to characterize fibrillar A β burden in persons with DS. Handen et al used Pittsburgh Compound B (PiB) PET to study seven 20-44 year-old DS/AD- participants and found evidence of fibrillar A β burden in the two individuals who were at least 38 years of age. Landt et al used PiB PET to study five DS/AD+ participants, four DS/AD- participants, and 14 NCs and found evidence of fibrillar A β burden after the age of 45.

Interpretation:

Our brain imaging study provides new information about the fibrillar A β , CMRgl, and GMV alterations associated with the clinical and preclinical stages of AD in participants with DS. DS subjects had florbetapir PET evidence of fibrillar A β burden in the symptomatic dementia stage. Further, fibrillar A β was detected in DS subjects without evidence of cognitive decline (DS/AD-) as early as 35 years of age (see figure 1). Increases in florbetapir uptake were associated with dementia status and older age. More specifically, florbetapir uptake strongly increases with and correlates with age. DS participants with AD dementia also had lower CMRgl and GMV in brain regions known to be preferentially affected by late-onset AD. Finally, DS participants with and without dementia had lower CMRgl and GMV than NC subjects in additional frontal regions. We believe these latter alterations may reflect differences in brain development.

Future directions:

The goal is to assess imaging characteristics in Down syndrome with and without dementia to determine when the changes occur. Do they proceed or coincide with cognitive decline? DS is associated with characteristic fibrillar A β , regional CMRgl, and regional GMV alterations in the symptomatic dementia stage and prior to onset of cognitive decline. Amyloid signal strongly increases with age in DS. Our brain imaging study provides a foundation for the longitudinal studies needed to inform AD treatment and prevention trials in this vulnerable population.

Figure 1.

a) Mean Cortical Florbetapir SUVRs, PC CMRgl, and hippocampal GMV in the DS/AD+, DS/AD-, and NC groups (top row). b) Associations between each of these measures and age in the overall DS and NC groups (bottom row).

Mean cortical florbetapir SUVR, posterior cingulate CMRgl, and hippocampal gray matter volumes. A) Greater florbetapir mean cortical-to-pons SUVR values for amyloid deposition (left); lower posterior cingulate CMRgl values (middle); and hippocampus gray matter volume (right) in DS/AD+, DS/AD- and in NC. B) Florbetapir mean cortical-to-pons SUVR values (left) and posterior cingulate CMRgl (middle), but not the hippocampus volume (right), had significantly greater association with age in DS participants (DS and DS/AD combined) than in NC.

Figure 2.

Statistical brain maps showing significantly greater cerebral-to-pontine florbetapir SUVRs in a) the DS/AD+ versus NC group, b) the DS/AD+ versus DS/AD- group, and c) the DS/AD- versus NC group. Significant CMRgl reductions ($P < 0.001$, uncorrected for multiple comparisons) are projected onto the lateral and medial surfaces of the brain.

Figure 3.

Statistical brain maps showing significantly lower CMRgl in a) the DS/AD+ versus NC group, b) the DS/AD+ versus DS/AD- group, and c) the DS/AD- versus NC group. Significant SUVR increases ($P < 0.001$, uncorrected for multiple comparisons) are projected onto the lateral and medial surfaces of the brain.

Figure 4. Statistical brain maps showing significantly lower GMV in a) the DS/AD+ versus NC group, b) the DS/AD+ versus DS/AD- group, and c) the DS/AD- versus NC group. Significant GMV reductions ($P = 0.001$, uncorrected for multiple comparisons) are projected onto the lateral and medial surfaces of the brain.

Table 1

Study Subject Demographic Characteristics, Clinical and Functional Ratings, and Neuropsychological Test Scores

	NC	DS/AD-	DS/AD+	Total	p-value
N	9	10	5	24	-----
Age	36±10	36±12	50±6 ^{†‡}	39±12	0.036
Gender (M/F)	6/3	4/6	2/3	12/12	*0.37, **0.58
MMSE	29±2	15±6 [†]	11±5 [†]	20±9	<0.001
SIB	99±1	87±9 [†]	75±26 [†]	90±14	<0.001
BPT	80±0	70±5 [†]	62±17 [†]	73±10	<0.001
DLD Cognitive	0±0	2±3 [†]	5±1 [†]	2±3	0.004
DLD Social	2±2	2±3	7±5	4±3	0.06
Vineland-Receptive	16±0	9±4 [†]	4±4 [†]	11±5	0.001
Vineland-Expressive	16±0	9±3 [†]	10±6 [†]	11±5	0.001
Vineland-Written	16±0	6±2 [†]	5±5 [†]	10±6	<0.001
Vineland-Personal	16±0	8±2 [†]	8±6 [†]	11±5	<0.001
Vineland-Domestic	16±0	9±3 [†]	8±4 [†]	12±4	<0.001
Vineland-Community	17±0	7±3 [†]	4±3 ^{†‡}	10±6	<0.001
Vineland-Interpersonal Relationships	16±0	10±2 [†]	10±1 [†]	12±3	<0.001
Vineland-Play and Leisure Time	16±0	10±1 [†]	8±3 [†]	12±4	<0.001
Vineland-Coping Skills	16±1	10±5 [†]	10±2 [†]	12±4	<0.001

mean ± sd

Raw scores are reported for the MMSE, SIB, BPT, and DLD;

Scaled scores are reported for all Vineland subtests;

Post-hoc groupwise comparisons:

* Fisher exact test p-value for NC and DS/AD-;

** Fisher exact test p-value for NC and DS/AD+

[†] significantly different from NC p<0.05

[‡] significantly different from DS/AD- p<0.05

Table 2

Cognitive measures correlating with imaging parameters.

		dmr_soc_sum	dmr_cog_sum	sib_tot	vin_comm_dom_ss	vin_gross
AV45 MC Pons	P	.005	.002	1.2e-4	.003	.001
	R	.556	.604	-.706	-.586	-.616
FDG Precuneus Pons	P	.021	.058	1.3e-4	.010	.002
	R	-.477	-.402	.714	.537	.605
FDG Precuneus Global	P	.010	.045	4e-4	.110	.006
	R	-.528	-.422	.676	.351	.554
MRI_Hippocampus Volume	P	.330	.841	.438	.898	.275
	R	-.213	.044	.170	.029	.238